A Japanese health ministry panel has endorsed two products using iPS cells, paving the way for the world's first practical ...

Tokyo-based K Pharma Inc. and Nikon Cell Innovation Co. on Tuesday signed a basic agreement on a new clinical trial project using induced pluripotent stem (iPS) cells to treat spinal cord injuries.

The earliest they are likely to become available is around summer, after drug pricing has been finalized. These products will ...

Japanese government experts endorsed on Thursday ground-breaking projects to manufacture regenerative medicine products to ...

Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

PALO ALTO, Calif., Jan. 30, 2026 /PRNewswire/ -- Leading GMP cell therapy CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells ...

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...

Japan Approves Worlds First iPS Therapies for Parkinsons, Heart Failure Conditional approval granted for Sumitomo Pharmas ...

Induced pluripotent stem cells (iPS cells) can be created from any tissue in the human body and possess the ability to transform into a wide range of tissues. Kobe University MARUYAMA Tatsuo and his ...

Japan's health ministry panel on Thursday approved the commercialization of two regenerative medicine products prepared from ...